At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 222 enrolled
Drug / intervention
SPARC Placebo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis
In Brief
A Phase 2 clinical trial evaluating SPARC Placebo, SPARC1310 I, and 2 other interventions for Seasonal Allergic Rhinitis. Completed, enrolled 222 participants across 1 site.
Detailed Summary
The study will assess the efficacy and safety of SPARC1310 when compared to placebo and active control
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 2013
Enrollment StartOct 2014
Primary CompletionDec 2014
TodayJul 2026
First PostedSep 12, 2013
Enrollment StartOct 1, 2014
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.8 years ago
Interventions
SPARC Placebodrug
Placebo
SPARC1310 Idrug
SPARC1310 I
SPARC1310 IIdrug
SPARC1310 II
SPARC1310 IIIdrug
SPARC1310 III